SCHEMBL1008522

SCHEMBL1008522

O=c1[nH]ncc(Oc2ccccc2)c1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 2/20 0.47
PKM P14618 1/20 0.44
TIPARP Q7Z3E1 2/20 0.44
TAAR1 Q96RJ0 1/20 0.43
ALOX15 P16050 1/20 0.43
ALOX12 P18054 1/20 0.43
ALDH1A1 P00352 4/20 0.43
NR1H2 P55055 1/20 0.41
POLB P06746 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
PARP1 P09874 1/20 0.40
PRKCI P41743 1/20 0.40
PDE4B Q07343 1/20 0.40
HSD17B10 Q99714 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
CYP11B1 P15538 1/20 0.39
CYP11B2 P19099 1/20 0.39
HAO1 Q9UJM8 1/20 0.39
NSD2 O96028 1/20 0.38
HSP90AA1 P07900 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11706621 0.81 BRD4 (0.48) BRD4ALOX15ALOX12ALDH1A1POLB
SCHEMBL11301660 0.79 BRD4 (0.46) BRD4ALOX15ALOX12ALDH1A1PARP1
SCHEMBL20818336 0.78 GSTP1 (0.50) BRD4PKMTIPARPTAAR1ALDH1A1
SCHEMBL1010609 0.76 PIN1 (0.43) PKMTIPARPTAAR1POLBSMN1; SMN2
SCHEMBL1008429 0.75 CTNNB1 (0.48) PKMTIPARPTAAR1SMN1; SMN2PARP1
SCHEMBL20443524 0.74 ALDH1A1 (0.50) PKMTIPARPTAAR1ALDH1A1POLB
SCHEMBL11495461 0.74 LTA4H (0.50) BRD4HAO1LMNA
SCHEMBL5844344 0.73 POLB (0.48) TIPARPALDH1A1POLBSMN1; SMN2HSD17B10
SCHEMBL20831305 0.72 SMN1; SMN2 (0.44) BRD4TIPARPALDH1A1SMN1; SMN2LMNA
SCHEMBL20818455 0.72 LTA4H (0.45) BRD4POLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 US disclosed
EP-2268633-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2011-01-05 EP disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed
WO-2009127544-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2009-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS GCK, GCKR, PDXK BRD4 2518/4885PKM 46/4885TIPARP 3034/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.